{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-029998","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.530869+00:00","generated_at":"2026-05-17T15:30:01.034825+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant Q1 loss widens to $0.33/share; completes $1.5B buyback, initiates new $500M program","bullets":["GAAP loss from continuing ops $273.9M ($0.33/share) vs income $31.6M ($0.01) YoY; revenue $2.2M down from $8.0M.","Non-GAAP loss from continuing ops $170.1M vs $107.1M YoY; R&D spend up $32.4M to $152.9M.","Completed $1.5B share repurchase program; board approved new $500M buyback in June 2025.","Cash, equivalents, restricted cash and marketable securities $4.5B; shares outstanding reduced >15% from Mar 2024.","Brepocitinib VALOR DM Phase 3 topline data H2 2025 (LPLV July); IMVT-1402 registrational trials started in GD, SjD June."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-029998","json":"https://secwatch.observer/filing/0001140361-25-029998.json","markdown":"https://secwatch.observer/filing/0001140361-25-029998.md","text":"https://secwatch.observer/filing/0001140361-25-029998.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/0001140361-25-029998-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125029998/ef20053385_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:30:01.034825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}